This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Octreotide LAR prolonged TTP vs placebo (14.3 vs 6.0 months; HR 0.34; P=0.000072) in 85 patients with metastatic midgut NETs.
Why it matters
PROMID was the first RCT establishing antiproliferative effects of a somatostatin analog in NETs.
The numbers in context
85 patients; TTP 14.3 vs 6.0 months; HR 0.34; P=0.000072
How the study worked
Phase 3, double-blind, placebo-controlled trial in metastatic midgut NETs.
Who was studied
Metastatic midgut NETs
What this study cannot tell us
Midgut only. Small sample. Included functional tumors.
Read the original research
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Journal of clinical oncology, 27(28), 4656-63
Citation
Rinke, Anja; Mueller, Hans-Helge; Schade-Brittinger, Carmen; Klose, Klaus-Jochen; Barth, Peter; Wied, Matthias; Mayer, Christoph; Aminossadati, Behrus; Pape, Ulrich-Frank; Blaeker, Michael; Wiedenmann, Bertram; Gress, Thomas M; Arnold, Rudolf; PROMID Study Group. (2009). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.. Journal of clinical oncology, 27(28), 4656-63. https://doi.org/10.1200/JCO.2008.18.0190